| 5.17 -0.15 (-2.82%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.16  |
1-year : | 7.94 |
| Resists | First : | 6.13 |
Second : | 6.8 |
| Pivot price | 5.77 |
|||
| Supports | First : | 5.06 |
Second : | 4.21 |
| MAs | MA(5) : | 5.32 |
MA(20) : | 5.94 |
| MA(100) : | 5.65 |
MA(250) : | 4.53 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 7.7 |
D(3) : | 7.1 |
| RSI | RSI(14): 37.4 |
|||
| 52-week | High : | 8.84 | Low : | 2.77 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ APRE ] has closed above bottom band by 9.3%. Bollinger Bands are 23.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.39 - 5.42 | 5.42 - 5.44 |
| Low: | 4.98 - 5.02 | 5.02 - 5.05 |
| Close: | 5.11 - 5.17 | 5.17 - 5.22 |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Tue, 26 Mar 2024
APRE Stock Quote Price and Forecast - CNN
Thu, 14 Mar 2024
Aprea Therapeutics director buys $50k of company stock - Investing.com
Thu, 14 Mar 2024
Aprea Therapeutics CFO buys $7,362 in company stock By Investing.com - Investing.com
Wed, 13 Mar 2024
Aprea Therapeutics Secures Funding and Advances Drug Pipeline - TipRanks.com - TipRanks
Mon, 11 Mar 2024
Aprea Therapeutics secures up to $34 million in financing - Investing.com
Mon, 11 Mar 2024
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.19e+006 (%) |
| Held by Institutions | 11.6 (%) |
| Shares Short | 70 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.546e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -26 % |
| Return on Assets (ttm) | 109.6 % |
| Return on Equity (ttm) | -36.7 % |
| Qtrly Rev. Growth | 583230 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 105830 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|